Osimertinib Improves Survival in EGFR+ NSCLC, Poses New Challenges for Resistance
Kazuhiko Nakagawa, MD, PhD, discusses the role of EGFR tyrosine kinase inhibitors for the frontline treatment of patients with <em>EGFR</em>-positive non–small cell lung cancer.